公司快评︱甘李药业与通化东宝业绩分化积极适应市场变化才是真龙头

每日经济新闻07-11

每经评论员贾运可在瞬息万变的市场环境中，即便是行业内的领头羊也并非永远稳固。通化东宝（SH600867，前收盘价8.04元，市值159.35亿元）与甘李药业（SH603087，前收盘价45.63元，市值274.33亿元）近期的业绩对比，恰如一面镜子，映照出市场龙头地位的脆弱性与不确定性，更昭示着，只有积极适应市场变化才是真龙头。具体来看，通化东宝预告上半年净利亏损2.24亿元，而上年同期为盈利...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2450809936?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-11 12:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2450809936","market":"sh","top_or_hot":-1,"title":"公司快评︱甘李药业与通化东宝业绩分化 积极适应市场变化才是真龙头","media":"每日经济新闻","content":"<div>\n<p>每经评论员 贾运可在瞬息万变的市场环境中，即便是行业内的领头羊也并非永远稳固。通化东宝（SH600867，前收盘价8.04元，市值159.35亿元）与甘李药业（SH603087，前收盘价45.63元，市值274.33亿元）近期的业绩对比，恰如一面镜子，映照出市场龙头地位的脆弱性与不确定性，更昭示着，只有积极适应市场变化才是真龙头。具体来看，通化东宝预告上半年净利亏损2.24亿元，而上年同期为盈利...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711120406af91c170&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>公司快评︱甘李药业与通化东宝业绩分化 积极适应市场变化才是真龙头</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n公司快评︱甘李药业与通化东宝业绩分化 积极适应市场变化才是真龙头\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-11 12:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711120406af91c170&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>每经评论员 贾运可在瞬息万变的市场环境中，即便是行业内的领头羊也并非永远稳固。通化东宝（SH600867，前收盘价8.04元，市值159.35亿元）与甘李药业（SH603087，前收盘价45.63元，市值274.33亿元）近期的业绩对比，恰如一面镜子，映照出市场龙头地位的脆弱性与不确定性，更昭示着，只有积极适应市场变化才是真龙头。具体来看，通化东宝预告上半年净利亏损2.24亿元，而上年同期为盈利...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711120406af91c170&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600867","symbol_name":"通化东宝","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711120406af91c170&s=b","article_id":"2450809936","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711120406af91c170&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2450809936","pubTimestamp":1720670624,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"通化东宝与甘李药业近期的业绩对比，恰如一面镜子，映照出市场龙头地位的脆弱性与不确定性，更昭示着，只有积极适应市场变化才是真龙头。甘李药业的成功，得益于其在接续集采中的灵活应变和策略调整。通化东宝则在新一轮胰岛素集采中未能守住既有优势，销售收入下滑，导致业绩预亏。甘李药业通过改进集采策略，抢到了更多市场份额，这是策略调整的胜利。而通化东宝未能及时应对市场变化，失去了既有优势。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600867":"通化东宝","603087":"甘李药业","BK0196":"行业龙头","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"Company Quick Review | Gan & Lee Pharmaceuticals and Tonghua Dongbao's performance differentiation is the real leader by actively adapting to market changes","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600867":1,"603087":1},"content_text":"每经评论员 贾运可在瞬息万变的市场环境中，即便是行业内的领头羊也并非永远稳固。通化东宝（SH600867，前收盘价8.04元，市值159.35亿元）与甘李药业（SH603087，前收盘价45.63元，市值274.33亿元）近期的业绩对比，恰如一面镜子，映照出市场龙头地位的脆弱性与不确定性，更昭示着，只有积极适应市场变化才是真龙头。具体来看，通化东宝预告上半年净利亏损2.24亿元，而上年同期为盈利4.848亿元，而甘李药业预计实现净利2.9亿元至3.3亿元，同比增加116.17%至145.98%。甘李药业的成功，得益于其在接续集采中的灵活应变和策略调整。在上一轮胰岛素集采中，甘李药业因激进的报价策略导致毛利率过低，未能支撑起足够的市场份额，最终业绩亏损。然而，在今年的接续集采中，甘李药业吸取教训，调整策略，以更加理性的报价获取更多份额，同时实现价格的小幅上涨，成功扭转了业绩。通化东宝则在新一轮胰岛素集采中未能守住既有优势，销售收入下滑，导致业绩预亏。其解释中提到，新一轮胰岛素集采在全国各省市落地实施，中标价格下降，销售收入同比减少约5.38亿元。此外，公司对集采实施前的库存产品进行了价格差额的冲销和返还，减少净利润约0.61亿元，同时终止了一项可溶性甘精赖脯双胰岛素注射液的研发工作，进一步减少净利润2.70亿元。这一现象不仅反映了胰岛素市场的激烈竞争，也凸显了企业在面临集采和市场变化时，策略调整与应变能力的重要性。甘李药业通过改进集采策略，抢到了更多市场份额，这是策略调整的胜利。而通化东宝未能及时应对市场变化，失去了既有优势。此外，在当前的市场环境中，胰岛素企业不仅需要在集采中保持竞争力，还需关注国际化发展。甘李药业在国际市场上也取得了一定进展，截至2023年底，其胰岛素产品已在20个海外国家获批，2023年国际销售收入同比增长131.78%。这种国际市场的拓展，为其业绩增长提供了新的动力。此次事件对行业和投资者都有重要的警示意义。对于企业而言，需要在激烈的市场竞争中，不断调整策略，提升应变能力，以应对集采和市场变化带来的挑战。对于投资者而言，应关注企业的市场策略和国际化发展，不盲目跟风，深入了解企业的实际业务和财务状况，避免因市场炒作而蒙受损失。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450809936"}

公司快评︱甘李药业与通化东宝业绩分化 积极适应市场变化才是真龙头

精彩评论

公司快评︱甘李药业与通化东宝业绩分化积极适应市场变化才是真龙头